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Abstract 26 
Pyrazinamide (PZA) is one of only two sterilizing drugs in the first-line anti-tuberculosis regimen. 27 
Its activity is strongly pH-dependent; the minimum inhibitory concentration changes by several 28 
orders of magnitude over a range of pH values that may be encountered in various in vivo 29 
compartments. We recently reported selective inactivity of PZA in a subset of C3HeB/FeJ mice 30 
with large caseous lung lesions. In the present study we evaluated whether such inactivity was 31 
explained by poor penetration of PZA into such lesions or selection of drug-resistant mutants.  32 
Despite demonstrating similar dose-proportional PZA exposures in plasma, epithelial lining fluid 33 
and lung lesions, no dose response was observed in a subset of C3HeB/FeJ mice with the highest 34 
CFU burden. Although PZA-resistant mutants eventually replaced the susceptible bacilli in 35 
BALB/c mice and in C3HeB/FeJ mice with low total CFU burdens, they never exceeded 1% of the 36 
total population in non-responding C3HeB/FeJ mice.  The selective inactivity of PZA in large 37 
caseous lesions of C3HeB/FeJ mice is best explained by the neutral pH of liquefying caseum. 38 
 39 
 40 
Introduction 41 
Pyrazinamide (PZA) is one of only two drugs proven to be capable of shortening the duration of 42 
treatment for tuberculosis (TB) to less than 12 months (1, 2). Although it has been a part of first-43 
line treatment regimens for 40 years, its mechanism of action remains incompletely understood 44 
(3, 4). PZA is a pro-drug that is converted to the active moiety pyrazinoic acid (POA) by a 45 
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bacterial amidase encoded by pncA (3). The MIC of both PZA and POA against M. tuberculosis is 46 
profoundly pH-dependent, changing by several orders of magnitude over the range of pH values 47 
that may be encountered in vivo. For example, the PZA MIC is 1000 µg/ml at a pH of 6.8, 50 48 
µg/ml at a pH of 5.5, and theoretically as low as 5µg/ml at a pH of 4.5, which M. tuberculosis 49 
may encounter in the phagolysosome of activated macrophages (5-7). Thus, just as its activity in 50 
vivo is assumed to vary according to drug exposures at the site of infection, it also should vary 51 
significantly according to the pH at the site of infection.  52 
The treatment-shortening, or sterilizing, effect of PZA in human TB is not readily evident in its 53 
early bactericidal activity (EBA), as measured by the average daily fall in sputum CFU count over 54 
the first 14 days of treatment. The EBA of PZA monotherapy ranges from 0.04 to 0.1 55 
log10CFU/ml/day (8, 9). When administered in combination with isoniazid and rifampin, its 56 
contribution to the EBA of the regimen may be undetectable (8). Instead, the contribution of 57 
PZA is more evident during the later phase of sputum sterilization (8, 10). It is remarkable then 58 
that PZA exerts its treatment-shortening effect in the modern short-course regimen only during 59 
the first 2 months of treatment. Extending the duration of treatment has no additional benefit, 60 
in both humans and murine models (3, 11, 12).  61 
Taken together, these characteristics suggest that PZA exerts its unique sterilizing effect against 62 
a subpopulation of tubercle bacilli residing in one or more specific compartments where the pH 63 
is sufficiently low to make the bacilli more susceptible to PZA than to other drugs. Where such 64 
subpopulations reside remains incompletely understood. It has been proposed that PZA acts 65 
against bacilli in inflammatory lung lesions where the pH is presumed to be acidic (e.g., 5.5-6.0) 66 
initially and then to increase as the lesions resolve with effective treatment (13). Alternatively, 67 
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the acidic milieu may persist but the bacillary sub-population that resides in that milieu making 68 
it more susceptible to PZA than to another first-line drug (e.g., rifampin), may simply be 69 
eradicated after 2 months of first-line therapy.  70 
Active TB in humans is characterized by a variety of lesion types in which M. tuberculosis 71 
encounters different microenvironments. Although no single non-clinical model of TB 72 
recapitulates all aspects of human TB, existing models may be used in a complementary fashion 73 
to better understand the impact of lesion type and resultant microenvironmental conditions on 74 
the action of PZA in human disease (14, 15). Based on pharmacodynamics studies in an in vitro 75 
hollow fiber model of TB, Gumbo et al proposed that PZA exerts its sterilizing effect against 76 
extracellular bacilli because PZA accumulates to concentrations high enough to produce its 77 
observed EBA at pH of 5.8 only in alveolar epithelial lining fluid (ELF) (16), and not inside 78 
alveolar macrophages (17). However, there is no direct evidence that the ELF or the caseous 79 
material inhabited by extracellular M. tuberculosis in vivo is indeed this acidic. Moreover, PZA 80 
clearly exerts substantial bactericidal and sterilizing activity against established M. tuberculosis 81 
infection in BALB/c mice, where the infecting bacilli are virtually all intracellular. In fact, 82 
bactericidal activity is evident in BALB/c mice at doses producing plasma exposures 83 
approximately half those produced by standard human doses (e.g., 75 mg/kg in mice), both 84 
alone and in combination with rifampin and isoniazid (18). The pronounced effect of PZA in the 85 
intracellular compartment is presumably due to the more acidic milieu in the phagolysosomes 86 
of activated macrophages, where the pH can be as low as 4.5 (6, 7), making PZA capable of 87 
significant sterilizing effects. The key role of macrophage activation in optimizing PZA effect is 88 
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further supported by the poor activity of PZA in mice prior to the onset of the adaptive immune 89 
response and in athymic nude mice (19, 20). 90 
C3HeB/FeJ mice have recently garnered significant attention as a murine TB model because, 91 
unlike BALB/c and other commonly used mouse strains, they develop caseous lung lesions in 92 
response to infection with M. tuberculosis (21-23). As expected, bacilli in the caseous core of 93 
these lesions are extracellular, while the cellular cuff of caseous granulomas and other non-94 
necrotic cellular granulomas harbor intracellular bacilli. Moreover, due to differences in the rate 95 
and extent of development of caseous lesions, significant heterogeneity in the presence, size 96 
and degree of liquefaction of caseous lesions is often observed between mice and between 97 
lesions within the same mouse at the initiation of treatment. We recently described a surprising 98 
phenomenon of dichotomous activity of PZA in C3HeB/FeJ mice (24), whereby PZA had little or 99 
no detectable bactericidal activity in a subset of mice with large caseous lesions despite 100 
demonstrating the expected bactericidal effect in those with less extensive disease and in a 101 
parallel cohort of BALB/c mice. Based on this apparent lesion-dependent activity, we 102 
hypothesized that this dichotomous effect of PZA was due to its limited activity against 103 
extracellular bacilli in caseum, which comprise the majority population in C3HeB/FeJ mice with 104 
large caseous lesions, but bactericidal effects on the smaller numbers of bacilli in cellular lesions 105 
of BALB/c and C3HeB/FeJ mice and in the cellular cuff of necrotic granulomas of C3HeB/FeJ 106 
mice. However, in C3HeB/FeJ mice with large caseous lesions, the effect against intracellular 107 
bacilli is largely obscured by the limited effect on the majority bacillary population in caseum.  108 
In the present study we set out to determine whether this selective inactivity of PZA in large 109 
caseous lesions could be explained by reduced drug penetration, selection of PZA-resistant 110 
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mutants, or insufficiently acidic conditions for PZA activity at achievable PZA concentrations. 111 
The results indicate that the near neutral pH of liquefying caseum prevents PZA from exerting 112 
any significant bactericidal activity against the numerous extracellular bacilli in larger caseous 113 
lesions and support the concept that pronounced sterilizing effects of PZA are exerted against 114 
intracellular bacilli.  115 
Portions of the results of this study have been presented previously at the International 116 
Workshop on the Clinical Pharmacology of Tuberculosis Drugs (Abstract No. 12, Washington, 117 
DC, September 2014), and the Interscience Conference on Antimicrobial Agents and 118 
Chemotherapy (Abstract No. A-20, Washington, DC, September 2014). 119 
 120 
Materials and methods 121 
Mycobacterial strains  122 
M. tuberculosis H37Rv was used as a frozen stock prepared from a log-phase culture in 123 
Middlebrook 7H9 broth after mouse passage and was diluted in 7H9 broth supplemented with 124 
10% OADC (Oleic acid Albumin Dextrose Catalase) before infection.  125 
Drugs and Chemotherapy 126 
PZA was obtained from Acros Organics (Thermo Fisher Scientific, New Jersey) and formulated 127 
for oral administration in distilled water. The daily doses were (in mg/kg) 10, 30, 100, 150, 300 128 
and 900. The most highly concentrated dosing solutions were warmed before administration to 129 
keep PZA in solution. 130 
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Doses were administered once daily, 5 days/week, by oral gavage, except for the 900mg/kg 131 
dose, which was administered as 450mg/kg twice daily (BID) due to solubility issues. 132 
Mouse aerosol infection  133 
All animal procedures were approved by the Animal Care and Use Committee of Johns Hopkins 134 
University. Female BALB/c mice (Charles River, Wilmington, MA) and C3HeB/FeJ mice (Jackson, 135 
Bar Harbor, ME) were used. Age of the mice varied between 1.5 and 10 months.  136 
Mice were aerosol infected using the Inhalation Exposure System (Glas-Col, Terre Haute, IN) 137 
with dilutions of a titered frozen stock of M. tuberculosis H37Rv to implant into the lung 138 
approximately 100-250 colony-forming units (CFU) for BALB/c and 50-100 CFU for C3HeB/FeJ 139 
mice. One day after infection, 4 mice from each aerosol run were humanely killed to determine 140 
the number of bacteria implanted.  141 
Guinea pig aerosol infection  142 
Female Hartley guinea pigs (Charles River, Wilmington, MA) 6-7 weeks old were aerosol infected 143 
with M. tuberculosis CDC1551 using the Madison Chamber as previously described (25). 144 
 145 
Pharmacokinetic studies 146 
Several pharmacokinetic (PK) studies were performed in C3HeB/FeJ mice to enable comparisons 147 
with results in BALB/c mice. The single dose plasma and lung concentration-time profiles were 148 
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determined in both 6-7 week-old and 8-10 month-old mice. Steady state plasma and lung 149 
concentration-time profiles were determined in infected 5-10 month-old mice.  150 
PZA concentrations were measured in samples of plasma, epithelial lining fluid (ELF) and lung 151 
lesions obtained, depending of the study, at 0.08, 0.25, 0.45, 1.5, 3, 5, 7, 12 and 17 hours after 152 
PZA dosing. Three or four mice from each dose group were sampled at each time point. Plasma 153 
was obtained either by tail vein bleed or by cardiac puncture performed under anesthesia by 154 
isoflurane inhalation. ELF was obtained after centrifugation of bronchoalveolar lavage fluid 155 
(BALF) at 400 x g for 5min. BALF was obtained, after anesthesia by intra peritoneal injection of 156 
Ketamine (200mg/kg) + Xylazine (10mg/kg), by injection and aspiration of 300µl of phosphate 157 
buffered saline (PBS) via a 20G IV catheter (ProtectIV® Plus, Smith Medical ASD, Southington, 158 
CT). The procedure was performed under visual control using an optic fiber (UV/VIS Fiber 159 
0.22NA, 400µm; Edmund Optics, Barrington, NJ) and a fiberscope light source. Lung lesions 160 
were obtained by resecting single or coalescing tubercular lesions, minimizing the amount of 161 
normal-appearing lung resected to obtain at least 20mg of tissue. Lungs were rinsed in cold PBS 162 
and lesions were resected on dry ice to prevent PZA diffusion or degradation.  163 
Samples were frozen at -80°C before being shipped to the Dartois laboratory, Rutgers New 164 
Jersey Medical School, for quantification. 165 
Quantification of PZA in samples 166 
PZA standards were obtained from Acros Organics (Thermo Fisher Scientific, New Jersey). 167 
Analytes of interest were extracted by diluting 50µL of mouse serum with 50µL of 168 
acetonitrole:water (1:1), and 450µL of methanol:acetonitrile (1:1) containing 0.5µg/ml of 169 
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pyrazinamide-15N,d3 or pyrazinecarboxylic acid-d3 (Toronto Research Chemicals, Inc) as internal 170 
standards. The mixture was vortexed and centrifuged, and 200µL of the supernatant was 171 
recovered for analysis. LC/MS-MS analysis was performed with an Agilent 1260 system coupled 172 
to an AB Sciex 4000 Q-trap Mass Spectrometer (positive mode electrospray ionization), and an 173 
Agilent column SB-C8, 4.6 x 75mm, 3.5µm, with the column temperature fixed at 24 °C. Mobile 174 
phase A was 0.1% formic acid in 100% H2O and mobile phase B was 0.1% formic acid in 100% 175 
acetonitrile. Injection volumes were routinely 2µL. The Mass Selective Detector was set to MRM 176 
(multiple reaction monitoring) mode using positive polarity ionization, monitoring for the ions 177 
of interest (m/z 124.0/81.1 for PZA) and the internal standard (m/z 296/215). The lower limit of 178 
quantification was 0.2µg /ml. 179 
The urea method was used to correct for dilution of ELF by PBS in BALF samples, as previously 180 
described (16). Thus the concentration of PZA in ELF (ZELF) was derived from the following 181 
relationship: ZELF= ZBAL x (VBAL/(VBAL x (UBAL/UPLA))) where ZBAL is the concentration of PZA 182 
measured in BALF, VBAL is the volume of BALF, UBAL is the concentration of urea in BALF, and UPLA 183 
is the concentration of urea in plasma. Five µl of plasma and 20µl of ELF were used with the 184 
QuantiChrom® urea assay kit (Gentaur, San Jose, CA), following manufacturer’s instructions. 185 
PK parameters (area under the concentration-time curve (AUC0-t, AUC0-∞), Cmax, half-life) were 186 
calculated from mean concentration data using Microsoft Excel (Office 2010, Microsoft Corp, 187 
Redmond, WA). AUC was calculated using the linear trapezoidal rule. Half-life and elimination 188 
rate constant were calculated by linear regression using semi-logarithmic concentration versus 189 
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time data. Concentration values below the lower limit of quantification were excluded from the 190 
pharmacokinetic evaluation. 191 
Pharmacodynamics study 192 
To determine dose-ranging efficacy of PZA, 60 BALB/c and 60 C3HeB/FeJ 6-week-old mice 193 
received 10, 30, 100, 300 and 450BID mg/kg of PZA for up to 8 weeks, beginning 6 weeks after 194 
infection. Treatment efficacy was assessed on the basis of lung CFU counts determined after 3 195 
and 8 weeks of treatment. Serial dilutions of whole lung homogenates were plated on selective 196 
Middlebrook 7H11 agar (Becton Dickinson, Franklin Lake, NJ). Plates were incubated for 6 to 8 197 
weeks at 37°C before determining final CFU counts. At the 8 week time point, quantitative 198 
cultures were performed with 0.5ml of lung homogenates on the same 7H11 agar 199 
supplemented with 900 mg/L of PZA (which is 3-6 times the MIC against the parent H37Rv strain 200 
on this media). 201 
Whole genome sequencing of PZA-resistant mutants 202 
Genomic DNA extraction procedures were adapted from a previously described cetyltrimethyl 203 
ammonium bromide (CTAB)-lysozyme method (26). From 1 to 5 colonies per mouse were picked 204 
from PZA-containing plates and streaked on 7H11 agar to amplify the clone. Colonies were 205 
scraped and suspended by bead-beating (2mm sterile beads) in 5ml of PBS. Three ml of 206 
supernatant was centrifuged for 2 min (3340 x g) before the pellet was heat killed (30min at 207 
80°C) in 200µL of Tris-EDTA buffer (TE buffer, Gaithersburg, MD). After 5 min of centrifugation 208 
(3340 x g), the pellet was incubated at 37°C overnight in 100µL of lysozyme. The extract was 209 
incubated at 65°C twice for 10 min, once after addition of 20 µl of 5% sodium dodecylsulfate 210 
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(Bio-Rad, Hercules, CA) and 20 µl of 1mg/ml Proteinase K (Thermo Scientific, Waltham, MA), and 211 
once after addition of 20 µl of 3M NaCl and 10 µl CTAB/NaCl solution. After adding 212 
chloroform:isoamylalcohol (24:1, v:v) the solution was centrifuged for 8 min at 15680 x g. The 213 
top layer was transferred in another tube containing 340µl of ice cold isopropanol before 214 
precipitating nucleic acids at -20°C for 30 minutes. After another centrifugation at 15680 x g for 215 
15min, the pellet was washed with ice cold 70% ethanol and then dissolved in 20µl of pure 216 
water after a second centrifugation. 217 
Samples were sequenced on an Illumina GAIIx next-generation sequencer. DNA samples were 218 
prepared for sequencing using the standard genomic DNA sample preparation protocol 219 
(Illumina Inc., San Diego, CA). Paired-end data was collected with a read length of 54+54 bp. 220 
Base-calling was performed using RTA 1.9.35, and genome assembly was carried out using a 221 
comparative assembly technique as described in (27), using the genome of H37Rv as a reference 222 
sequence. The mean depth of coverage over all samples was 29.5x. 223 
Assessment of pH of the lesions 224 
The pH of liquefied caseum from selected lesions of more than 3mm diameter was measured 225 
with a 16G needle tip micro-pH comb electrode (Thermo Scientific Orion, Chelmsford, MA) and 226 
a benchtop pH meter Mettler Toledo FE20 (Business Unit Analytical, Schwerzenbach, 227 
Switzerland). The probe was inserted directly into the tubercle to measure the pH of the 228 
liquefied material. 229 
Data Analysis 230 
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Lung CFU counts (x) were log-transformed as log10 (x + 1) before analysis. Group mean CFU 231 
counts after 2 months of treatment were compared using one-way analysis of variance with 232 
GraphPad Prism v.5 (GraphPad Software, San Diego, CA) and Bonferroni’s posttest to adjust for 233 
multiple comparisons, as appropriate. A non-linear dose-response regression was used to 234 
calculate PZA dose-response using the same software. 235 
  236 
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Results 237 
Pharmacokinetics of PZA 238 
 Uninfected mice 239 
Total daily doses from 10 to 900mg/kg of PZA were administered. As stated in the methods 240 
section, PZA was administered orally once a day, except for 900 mg/kg which was administered 241 
as two 450mg/kg doses given 12 hours apart (BID). PZA concentrations were measured in 242 
plasma and ELF. 243 
As shown in Figure 1 uninfected C3HeB/FeJ mice had at least dose proportional (possibly supra-244 
proportional) exposures in plasma and also in ELF (data not shown). The PK parameter values 245 
for plasma are presented in Table 1 and were comparable to previous published results (28). 246 
The concentrations produced by the lowest doses of PZA were not quantifiable in ELF because 247 
of the high dilution factor. The median ratio of ELF/plasma concentrations ranged between 0.9-248 
3 at 3h and tended to increase slightly over time to 1.2-3.7 independently of dose (except for 249 
300mg/kg, where the ratio decreased) (Table 2).  250 
 Infected mice 251 
Infected C3HeB/FeJ mice  received 150mg/kg once daily or 450mg/kg BID doses of PZA for 3 252 
days or 4 weeks before PZA concentrations were measured in plasma, ELF and tubercular 253 
lesions. No major difference was observed in plasma PZA concentrations between infected and 254 
uninfected mice, although AUC and Cmax were numerically lower in infected mice receiving 255 
450mg/kg BID compared to uninfected mice (Table 1). Plasma PK parameters in infected 256 
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C3HeB/FeJ mice were comparable to past results in infected BALB/c mice (28) (Table 1). The 257 
dose proportionality was conserved both in plasma (Figure 2) and in ELF. In ELF, PZA 258 
concentrations seemed to be more variable between mice and between experiments than what 259 
was observed in plasma (data not shown). The ratio of PZA concentrations in ELF/plasma in 260 
infected mice was similar to that observed in uninfected mice (Table 2). 261 
The concentrations of PZA in lesions largely mirrored concentrations in plasma (Figure 2). The 262 
measurements from a representative large necrotic granuloma sampled 7h after a dose of 263 
150mg/kg were similar for the capsule and the liquefied caseum (2.68 and 1.76µg/ml 264 
respectively). When comparing PZA concentrations in lesions of mice with large necrotic 265 
granulomas (>3mm) and mice without such lesions, at the same time points, means tended to 266 
be higher in larger lesions than in smaller lesions. For example, in samples obtained 90min after 267 
a 150mg/kg dose, 3 large lesions had a mean PZA concentration of 105.1µg/ml whereas 3 268 
smaller lesions averaged 80.1µg/ml, but the difference was not statistically significant (p=0.07). 269 
In samples obtained 7h after the same dose, 3 large lesions had a mean PZA concentration of 270 
3.5µg/ml whereas 2 smaller lesions averaged 2µg/ml (p=0.055). The median ratios of 271 
lesion/plasma concentration were 0.8 and 0.7 at 1.5h for 150mg/kg and 450mg/kg BID 272 
respectively, and remained stable between 0.8-1.2 over time.  273 
Pharmacodynamics of PZA 274 
In the dose-ranging efficacy study, BALB/c and C3HeB/FeJ mice received daily doses ranging 275 
from 10 to 450 BID mg/kg of PZA for 3 to 8 weeks. Mean (SD) CFU counts at the start of 276 
treatment (D0) were 6.86 (0.17) for BALB/c mice and 7.09 (0.12) for C3HeB/FeJ mice. As 277 
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previously described (24), PZA was associated with a dichotomous dose-response relationship in 278 
C3HeB/FeJ mice but not in BALB/c mice. Dose-proportional bactericidal activity was observed in 279 
BALB/c mice and in most C3HeB/FeJ mice at each time point. At doses of 100 mg/kg and above, 280 
the bactericidal effect size increased between 3 and 8 weeks of treatment. After 8 weeks, 281 
increasing the dose from 30 to 300mg/kg increased the log-kill by 2 log10, and increasing the 282 
dose from 300 mg/kg to 450 mg/kg BID increased the log-kill by another 2 log10 in both mouse 283 
strains (Figure 3). However, no dose response effect was observed in a subset of C3HeB/FeJ 284 
mice, even after 8 weeks of treatment (Figure 3). CFU counts after 8 weeks in these poor 285 
responders were one-half to one log lower compared to week 3, so some modest activity could 286 
not be excluded. Excluding these outliers, the goodness of fit of the logarithmic dose-response 287 
curve was r²=0.92 at week 3 and 0.87 at week 8; the maximum effect (Emax) at week 3 was 288 
3.27log10 and the dose producing 50% of the Emax (EC50) was 128.4mg/kg (95% confidence 289 
interval [CI] = 58.32-281.2). Similar curve fits and parameters were observed in BALB/c mice, 290 
e.g., the goodness of fit was r²=0.87 and 0.98 at weeks 3 and 8 respectively; Emax was 3.06log10 291 
and EC50 was 139.6mg/kg (95%CI = 61.26-318.1) at week 3.  292 
Selection and characterization of PZA-resistant mutants 293 
After 8 weeks of treatment, 11 (37%) of 30 BALB/c mice had colonies on PZA-containing plates, 294 
compared to 18 (75%) of 24 C3HeB/FeJ mice (p < 0.01). Resistance among BALB/c mice was only 295 
observed at PZA doses ≥100mg/kg, whereas resistance among C3HeB/FeJ mice was observed at 296 
all dose levels. Despite the proclivity towards selection of resistant mutants in C3HeB/FeJ mice, 297 
replacement of the PZA-susceptible bacillary population with PZA-resistant mutants did not 298 
explain the poor activity of PZA in those with the highest CFU counts at the end of treatment. 299 
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Indeed, the greatest proportion of PZA-resistant CFU compared to total CFU was among those 300 
C3HeB/FeJ mice receiving the highest PZA doses in which the greatest bactericidal activity was 301 
observed (where up to 100% of the total population was resistant to PZA). On the contrary, 302 
among mice in which PZA did not exhibit bactericidal activity, PZA-resistant mutants remained ≤ 303 
1% of the total CFU (Figure 4). Nevertheless, both the absolute number and the proportion of 304 
bacteria resistant to PZA tended to increase with dose among the poorly responding C3HeB/FeJ 305 
mice, indicating that PZA was likely exerting a bactericidal effect against drug-susceptible bacilli 306 
and promoting selective amplification of resistant mutants within a minority sub-population 307 
within these mice, likely in the intracellular compartment. The mean CFU counts of PZA-308 
resistant mutants were not statistically different between the 2 mouse strains (p=0.89, 0.11, 309 
0.17 for 100, 300 mg/kg and 450 mg/kg BID doses respectively). 310 
Although colonies from each mouse harboring resistant mutants were processed for whole 311 
genome sequencing, only 79% of colonies selected (20/27 for BALB/c and 53/65 for C3HeB/FeJ) 312 
were actually sequenced due to a variety of technical difficulties.  313 
With one exception, all sequenced colonies isolated on PZA-containing media had mutations in 314 
pncA, confirming the utility of employing3-6xMIC PZA concentrations in standard 7H11 agar (pH 315 
6.8) for isolating resistant mutants. In most cases, different colonies from the same mouse 316 
harbored the same pncA mutation. Out of 13 C3HeB/FeJ mice with several colonies sequenced, 317 
2 mice had 3 or more colonies with differing mutations in pncA, whereas 7 mice had 2 colonies 318 
with either of 2 different mutations, and 4 mice had colonies sharing only one mutation. Among 319 
5 BALB/c mice with several colonies sequenced, 2 mice had colonies with either of 2 different 320 
pncA mutations and 3 mice had colonies sharing only one mutation. Table 3 catalogs the 321 
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mutations identified, most of which have previously been reported as clinically relevant 322 
mutations likely to confer PZA resistance (29, 30). Notably, deletions spanning multiple open 323 
reading frames were quite frequent (8/29 for C3HeB/FeJ vs. 2/10 for BALB/c). Apart from 324 
deletions, seven different mutations in pncA were identified in BALB/c mice and 20 in 325 
C3HeB/FeJ mice. Each pncA mutation was observed in only one mouse. The only colony without 326 
a pncA mutation was selected in a C3HeB/FeJ mouse treated with 300mg/kg and harbored only 327 
an A3311T mutation in Rv3350c (PPE56). Three other colonies isolated from the same mouse 328 
had this mutation as well as identical 2 bp deletions in pncA. The fifth colony had no mutation in 329 
Rv3350c, only a different (G108R) mutation in pncA.  330 
pH assessment  331 
We recently reported that the pH of liquefied caseous material from lesions in C3HeB/FeJ mice 332 
was 7.39 ± 0.096 (range 7.19 - 7.54) (24). To extend our evaluation to another non-clinical 333 
species, we measured pH in 12 different lesions in 4 untreated guinea pigs infected for 13 334 
weeks. An average pH of 7.23 ± 0.17 (range 6.99 – 7.52) was found, only slightly lower than that 335 
of the adjacent normal-appearing lung (7.35 ± 0.22).  336 
  337 
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Discussion 338 
In a previous study we observed that PZA had limited activity in a subset of C3HeB/FeJ mice 339 
with large caseous lesions and hypothesized that this was due to the neutral pH of the liquefied 340 
caseum in such lesions (24). In this study we bring additional evidence in support of this 341 
hypothesis by demonstrating that neither poor distribution of PZA into caseous lesions nor 342 
selection of PZA-resistant mutants explains the limited PZA activity and the observed lack of 343 
dose-response effect. 344 
Indeed PZA exposures increased in a dose proportional fashion in plasma and ELF in both 345 
uninfected and infected mice and, at doses of 100 mg/kg or higher, met or exceeded plasma 346 
exposures observed in humans receiving PZA at doses recommended for TB treatment (16, 31). 347 
Moreover, PZA concentrations in the caseous lesions of infected C3HeB/FeJ mice also increased 348 
dose-proportionally and were, on average, 67% of the concurrent plasma concentration, a ratio 349 
similar to that recently observed in a rabbit TB model and consistent with evidence that PZA 350 
diffuses readily through caseum (32-34). To our knowledge, this is the first report of PZA 351 
concentrations in ELF in mice. Conte et al (16) described higher concentrations of PZA in ELF 352 
relative to plasma in uninfected human subjects (ratio ELF/plasma concentration of 13-24) than 353 
we observed in infected mice, except for the median ratio of 22.8 we observed in mice sampled 354 
12 hours after a 150mg/kg dose. This discrepancy may be due in part to the higher systemic 355 
clearance of PZA in mice allowing less accumulation in ELF compared to humans. However, 356 
determination of ELF concentrations of rapidly diffusing small molecules like PZA is also 357 
technically challenging because small differences in dwell time during bronchoalveolar lavage 358 
can introduce large differences in concentration due to rapid drug redistribution from tissue 359 
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into lavage fluid (35). If the drug in question distributes faster than urea, its ELF concentration 360 
could be over-estimated as the dwell time of the lavage fluid increases. Importantly, infection 361 
did not appear to increase the distribution of PZA into the ELF.  362 
As indicated by the lack of a dose-response effect in C3HeB/FeJ mice with large caseous lesions, 363 
achieving higher PZA concentrations are useful only if the pH of the actual lung compartment 364 
inhabited by M. tuberculosis is sufficiently acidic for PZA to exert its effect. According to Zhang’s 365 
model, intrabacillary accumulation of the active POA moiety increases inversely with the pH of 366 
the milieu (3). At neutral pH, the PZA MIC against M. tuberculosis H37Rv may exceed 1600 367 
µg/ml (5), which is 3-4 times higher than the highest average steady state ELF concentrations 368 
observed in uninfected mice in this study or at 4 hours post-dose in uninfected human subjects 369 
administered 1 g daily for 5 days (16), as well as in infected mice receiving a PZA dose (150 370 
mg/kg) that most closely approximates plasma AUCs observed in patients receiving 371 
recommended PZA doses. Only the Cmax in the ELF of infected mice receiving 450 mg/kg BID 372 
approached the MIC at neutral pH.  373 
Against cultures of M. tuberculosis H37Rv adjusted to a pH of 5.8 in an in vitro hollow fiber 374 
model of TB, Gumbo et al established that human-like exposures producing a PZA AUC of 375 
approximately 1500 µg.h/ml (i.e., AUC/MIC of 120 x MIC of 12.5) produces the same 0.11 376 
log10CFU/ml/day fall in CFU counts that was observed in 14-day clinical EBA trials (8, 17). 377 
Although the typical plasma AUC produced by standard PZA doses is only 300-500 µg.h/ml, the 378 
degree to which PZA was shown to accumulate in ELF provided a parsimonious explanation for 379 
sufficient target attainment in lung cavities, leading the authors to conclude that, because PZA 380 
does not accumulate above plasma concentrations inside cells, PZA most likely exerts its 381 
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sterilizing activity against extracellular bacilli. However, the bactericidal and sterilizing activity of 382 
doses producing clinically relevant plasma  PZA AUC values in commonly used mouse strains, in 383 
which virtually all bacilli are found intracellularly, is well demonstrated (11, 18, 36). In the 384 
present study, we found that after 15 doses of PZA administered to BALB/c mice, the EC50 of 385 
approximately 150 mg/kg produced a 0.102 log10CFU/dose reduction. The mean plasma AUC 386 
produced by this dose is 388 µg.hr/ml. Thus, a dose producing similar plasma AUC in BALB/c 387 
mice and humans produces similar EBA at exposures that are approximately one-quarter of the 388 
exposure required for the same effect in the hollow fiber system at pH of 5.8. The lower 389 
exposures needed to observe the same kill in mice compared to the hollow fiber would be 390 
explained if the pH in infected murine macrophages is closer to 5.0, a level that is attained by 391 
activated macrophages (7, 37).  392 
If extracellular bacilli are a target of PZA’s sterilizing activity, then the pH of the ELF or caseum in 393 
which they are found should be sufficiently low for the expected PZA concentrations to be 394 
active. For example, a pH of 5.8 was studied in the hollow fiber model (17). The technique of 395 
sampling ELF via BAL makes it difficult to measure ELF pH. However, it is possible to measure 396 
the pH of airway lining fluid in vivo. The pH of the tracheal lining fluid of anesthetized mice was 397 
reported to be 7.1 (38). Similarly, a study using a bronchoscopically directed pH electrode 398 
reported the pH of subsegmental bronchi to be 6.6 in humans (6.48 in patients presenting with 399 
bacterial pneumonia) (39). Our finding of a more neutral pH in caseum from C3HeB/FeJ mouse 400 
and guinea pig tubercles extends previous work in rabbits showing an increase in pH of caseum 401 
(from 6.4 to 7.4) as lesions mature, caseate and liquefy (40). We are aware of only one report of 402 
the pH of caseum from human cavities which described the pH of resected cavity tissue 403 
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homogenates as ranging between 6.1 and 7.4, but noted that the pH was 6.8 or above in 15 out 404 
of 17 lesions (41). This report is well in line with the aforementioned results from animal 405 
models. Taken together, these data run counter to the prevailing notion that caseum is acidic 406 
and make the assumption that extracellular bacilli routinely encounter conditions of pH ≤ 6.5 407 
rather tenuous (17).  408 
The remarkable dichotomous activity of PZA in C3HeB/FeJ mice in the present study confirms 409 
and extends our prior results (24). It also is consistent with the important role of pH in the 410 
action of PZA. Among those mice with less severe disease, the pharmacodynamics of PZA were 411 
similar to that observed in BALB/c mice, suggesting similar conditions wherever bacilli are found 412 
intracellularly in C3HeB/FeJ mice, such as in small cellular granulomas or in the cellular cuff of 413 
caseous granulomas. Based on the exposure-response relationship defined in the hollow fiber 414 
model (17), the PZA exposures attained inside mouse macrophages would not be expected to 415 
exert a bactericidal effect comparable to the EBA in humans unless the pH in the macrophage 416 
compartment was below 5.8 and closer to 5.0, a value attainable in activated macrophages (7). 417 
On the other hand, in those C3HeB/FeJ mice with large caseous lesions where the pH 418 
approaches 7.4 (24), little or no bactericidal activity of PZA was observed despite attaining 419 
plasma AUCs that are 3-5 times those produced in plasma at typical human doses but similar to 420 
the AUC associated with a 0.11 log10 CFU reduction per day at pH of 5.8 in the hollow fiber 421 
experiments (17). Moreover, the estimated PZA AUC in these lesions of approximately 850 422 
µg.h/ml is the same as that associated with a 2 log kill over 28 days in the hollow fiber 423 
experiments. Taken together, these results are consistent with the idea that local pH has a 424 
profound effect on PZA activity.  425 
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The facts that PZA exerts its sterilizing contribution during the first 2 months of treatment in the 426 
current first-line regimen and that patients unable to take PZA can still be cured when rifampin-427 
containing regimens are given for 9 months rather than the usual 6 months with PZA (42), 428 
suggests that the bacillary population eradicated by PZA is not susceptible only to PZA, just 429 
more susceptible to PZA than to rifampin, and that this population is of a limited size. When the 430 
pH is 6.5 and above, it is unlikely that PZA exposures routinely achieved in TB patients will 431 
produce the kind of bactericidal effect that will lend significant additive sterilizing activity to the 432 
first-line regimen. The high pH of the caseum lining the cavity wall likely explains the limited 433 
contribution of PZA to the activity of the first-line regimen over the first 14 days of treatment. 434 
There is ample evidence however, that PZA contributes to the sterilization of sputum cultures 435 
later in the initial phase in patients receiving the first-line regimen, including recent evidence 436 
that this contribution is exposure-dependent (10). While the poor results in mice with large 437 
caseous lesions seems inconsistent with the well-known treatment shortening potential of PZA 438 
in humans, the results may be quite consistent if one considers its sterilizing activity is only 439 
evident in the context of combination therapy. Our results suggest that while other drugs like 440 
rifampin and isoniazid eradicate the bacilli in caseous material, PZA eliminates a subpopulation 441 
that is likely residing inside macrophages, in phagolysosomes at low pH, where achievable PZA 442 
concentrations exceed the local MIC. The pH dependence of PZA activity, the near neutral pH of 443 
caseum across species, and the dramatic lesion-dependence of PZA activity in C3HeB/FeJ mice is 444 
compelling evidence that PZA exerts its most prominent sterilizing effects against intracellular 445 
bacilli. This model is not mutually exclusive with the model proposed by Gumbo et al in which 446 
PZA exerts activity against extracellular bacilli in sufficiently acidic environments. Rather, given 447 
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the remarkable heterogeneity observed in human TB, these models might be considered 448 
complementary. Further studies to evaluate the sterilizing activity of PZA in combination 449 
therapy and to isolate the lesions in C3HeB/FeJ mice in which PZA exerts a sterilizing effect are 450 
warranted. 451 
We found that, like C3HeB/FeJ mice and rabbits, guinea pigs develop necrotic lesions with 452 
neutral caseum by 13 weeks post-infection. Despite this, PZA has been reported to have 453 
bactericidal activity in guinea pigs (36). This apparent discrepancy may be explained by the fact 454 
that examinations of lung histopathology revealed only poorly formed granulomas and limited 455 
necrosis at the time of treatment initiation (4 weeks post-infection) and active doses of PZA 456 
were associated with reduced numbers and size of granulomas (at 8 weeks post-infection) (36). 457 
Thus, it is likely that PZA exerted its bactericidal effect against bacilli under low pH conditions 458 
inside activated macrophages rather than inside caseous regions. Further studies of PZA activity 459 
against more established disease in guinea pigs are warranted to test this hypothesis.  460 
PZA resistance was not the explanation for the dichotomous activity of PZA in C3HeB/FeJ mice, 461 
since resistant mutants never replaced the sensitive population in the mice with worst response 462 
to PZA. However, it is interesting to see that selective amplification of PZA-resistant mutants 463 
occurs more readily, including at lower doses, in C3HeB/FeJ mice compared to BALB/c mice 464 
(18/24 vs 11/30 respectively). Many C3HeB/FeJ mice receiving doses ≥ 100 mg/kg for 8 weeks 465 
harbored more than 0.1% PZA-resistant CFU, including mice in which the week 8 CFU count was 466 
likely not significantly lower than the D0 CFU count. This is evidence that, even when PZA was 467 
not exerting bactericidal effects on the largest population of bacilli in the large caseous lesions, 468 
it was exerting significant bactericidal activity against PZA-susceptible bacilli and selectively 469 
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amplifying PZA-resistant mutants in smaller granulomas and cellular lesions similar to those in 470 
BALB/c mice. The limited effect of PZA in liquefied caseum, where the highest bacterial counts 471 
are observed, may help to explain why PZA resistance typically emerges only after resistance to 472 
rifampin and isoniazid, and why PZA is not very effective at preventing the emergence of 473 
resistance to these and other companion agents that are bactericidal in that compartment (43). 474 
However, additional experiments comparing the selection of mutants resistant to PZA and to 475 
companion agents in large caseous lesions versus the rest of the lung are needed to confirm 476 
these results.  477 
PZA resistance was explained by pncA mutations in all mice. Virtually all of these mutations have 478 
been described in PZA-resistant clinical isolates and most of them were found only in PZA-479 
resistant isolates, adding to the evidence presented here that these mutations confer PZA 480 
resistance (30). Therefore, C3HeB/FeJ mice may be an excellent model to study factors 481 
associated with the selection of PZA-resistant mutants and the clinical significance of specific 482 
mutations. It is noteworthy that large multigenic deletions including pncA were observed in 483 
some PZA-resistant isolates from mice. Multigenic deletions are rare among reported clinical 484 
isolates (44, 45). However, they may be more difficult to detect by selective sequencing 485 
approaches commonly used with clinical isolates. 486 
 487 
Our study has important limitations. Firstly, we did not plate large caseous lesions in C3HeB/FeJ 488 
mice separately from the rest of the lung, which prevented specific confirmation of where the 489 
selective killing of PZA-susceptible bacteria and amplification of PZA-resistant mutants was 490 
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occurring. Secondly, in extrapolating the pH of TB lesion compartments from mice and other 491 
animal models to humans, we are limited by the scant data available on the pH of human 492 
caseum and the intracellular compartments inhabited by phagocytosed bacteria in vivo. 493 
Although further confirmation of the pH of human caseum is needed, the available data 494 
presented above suggest a similar pH across species. Although there is evidence that 495 
macrophages activated with interferon-gamma in vitro deliver M. tuberculosis to an acidic 496 
compartment with a pH as low as 4.5-5.0 (7), confirmation of delivery of Mtb to acidified 497 
phagosomes in a living infected host was elusive until recently (46). Still, new tools are needed 498 
to more accurately quantify the pH of intracellular vacuoles and other lesion compartments 499 
inhabited by M. tuberculosis in vivo in a manner that can be correlated with PZA 500 
pharmacodynamics. A third limitation is that, due to the more rapid clearance of PZA in mice 501 
compared to humans, the concentration-time profiles produced in our mice reproduced human 502 
AUCs but did not necessarily mimic the time course of PZA concentrations in humans. As 503 
mentioned above, this may be one reason for less accumulation of PZA in ELF of mice compared 504 
to humans. It also may lead to discordance between the relationships of important PK/PD-based 505 
exposure indices and targets to efficacy and therefore demands caution when extrapolating 506 
between mice and humans or the hollow fiber model, as we have here. A final limitation of this 507 
study is the high level of dilution (median=40, IQR=21-64) of ELF with PBS, which made the 508 
lower limit of PZA quantification higher than that of plasma. The technical limit of quantification 509 
in each sample was 0.2µg/ml, making the lower limit of quantification in ELF 4-13µg/ml. 510 
Furthermore BAL was performed with 300µL of PBS rendering infeasible to duplicate samples or 511 
to repeat runs when results were not within 20% of controls (1 case out of 11).  512 
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 513 
Conclusions 514 
In this study, we confirm that PZA has variable, lesion-dependent activity in C3HeB/FeJ mice in 515 
which poor PZA activity occurs in large caseous lesions due to the neutral pH of the caseum 516 
therein. Such lesion-dependent activity of PZA in C3HeB/FeJ mice, like that recently 517 
demonstrated for clofazimine and oxazolidinones (24, 47), promotes the C3HeB/FeJ mouse 518 
model as a valuable tool for studying the influence of lesion type and microenvironment on 519 
drug distribution and drug action, including the selection of drug-resistant mutants. Although 520 
additional studies to evaluate the contribution of PZA to the standard first-line regimen in 521 
C3HeB/FeJ mice are warranted, these results suggest that future investigations in C3HeB/FeJ 522 
mice may give a more holistic and nuanced appraisal of the potential contribution of PZA to 523 
novel regimens. 524 
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Tables and Figures 657 
Table 1: Plasma PK parameters of PZA in C3HeB/FeJ mice 658 
Infection status PZA dose (mg/kg) AUC0-24  
(µg.h/ml) 
Cmax  
(µg/ml) 
T1/2  
(h) 
Uninfected 
C3HeB/FeJ mice 
(single dose) 
10 9.2 5.6 0.6 
30 59.2 23 1 
150 577.9 187.8 1.4 
300 1,081.6 263 1.9 
450 BID 5,326.8 665.3 3.5 
Infected 
C3HeB/FeJ mice 
(steady state) 
150 455.6 166 1.3 
450 BID 3,589.6 467 1.6 
Infected BALB/c 
mice (single 
dose)  
150 (28) 388 163 1.2 
450 BID*  3241.8 472.9 2.3 
Legend: Parameters were calculated from mean concentration data. The data presented are 659 
from one of two representative experiments in each infection condition. *= unpublished data 660 
 661 
 662 
Table 2: Ratio of ELF/plasma PZA concentrations in C3HeB/FeJ mice. 663 
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 PZA dose 
(mg/kg) 
Time 
Median ELF/plasma ratio (number of mice) 
1.5h 3h 7h 12h 
Uninfected mice (single 
dose) 
30  1.2 (2) 3.7 (1)  
150  0.9 (7) 1 (4) 22.8 (4) 
300  2 (6) 1 (5)  
450 BID  1.1 (3) 2.2 (3) 1.2 (3) 
Infected mice (steady 
state) 
150 1.1 (6) 3 (7) 3.1 (8) NA 
450 BID 1.3 (6) 1.6 (8) 1.2 (7)  
Legend: NA=not applicable (due to non-quantifiable PZA concentration in ELF or in plasma). No 664 
PZA was measurable at 0h and 17h time point or in the 10mg/kg arm.  665 
 666 
  667 
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Table 3: Results of mutations in pncA gene (Rv2043c) observed in PZA-resistant isolates 668 
Type of 
mutation 
BALB/c mouse strain C3HeB/FeJ mouse strain 
Point 
mutations 
K96M   
G132A   
C138Y  
T142P   
L159V   
H171R 
M1I   
L19R   
A46E   
S67P   
H71Y   
C72F   
Y99stop  
G108R  
I133N   
T135P   
H137D   
V139M   
A146V   
S164P   
L172P  
E173stop 
Small Indels* +A in E127 -G in P54,  
-CG in A26,  
-T in I133 
-CGTCAGCGGTACTC in V73-P77 
Large-scale 
Deletions 
Rv2023c-Rv2048c (27 kb) 
Rv2027c-Rv2047c (19.8 kb) 
 
 
Rv2030c-Rv2048c (21 kb) 
Rv2034-Rv2045c (9 kb) 
Rv2039c-Rv2048c (13 kb)  
Rv2040c-Rv2045c (3.5 kb) 
Rv2041c-Rv2043c (1.1 kb)  
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Rv2042c-Rv2043c (1 kb) 
Rv2043c-Rv2044c (0.2 kb)  
5' UTR A>G -11 bp upstream  
No mutation - one (A3311T mutation in Rv3350c) 
Legend: *frame-shifts 669 
 670 
Figure 1 671 
 672 
Legend: Dose-ranging PZA concentration-time profiles in uninfected C3HeB/FeJ mice in plasma. 673 
Data are plotted as mean and SD. 674 
 675 
 676 
 677 
 678 
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Figure 2 679 
 680 
Legend: Dose-ranging PZA concentration-time profiles in infected C3HeB/FeJ mice in plasma 681 
(solid shapes) and lesions (open shapes) for 150 and 450 BID mg/kg. Panel A and panel B 682 
represents 2 different sets of experiment. Data are plotted as mean and SD. 683 
 684 
Figure 3 685 
  686 
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Legend: Dose-response profiles in C3HeB/FeJ mice (panel A) and BALB/c mice (panel B) after 3 687 
weeks (blue symbols and line) and 8 weeks (red symbols and line) of treatment (W3 and W8 688 
respectively). Open ellipse: C3HeB/FeJ mice excluded from curve fit (outliers). 689 
 690 
Figure 4 691 
10 30 100 300 900
0
2
4
6
8
10
Drug dose (mg/kg)
CF
U 
co
un
t (
log
10
/lu
ng
)
 692 
Legend: Total CFU counts (solid symbols) and PZA-resistant CFU counts (open symbols) in 693 
C3HeB/FeJ mice treated with escalating PZA doses. Each symbol shape represents an individual 694 
mouse in its dose group. Shown in blue are the CFU counts from mice considered to fit the 695 
dose-response curve shown in the inset. Shown in red are the CFU counts from mice considered 696 
non-responsive to the dose increase. Solid symbols indicate the total CFU counts determined on 697 
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drug-free media for each individual mouse. The open symbols indicate the resistant CFU counts 698 
determined on PZA-containing plates for the same mouse.  699 
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